Patents by Inventor Kevin Duane Bunker

Kevin Duane Bunker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzamide compounds
    Patent number: 11590126
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: February 28, 2023
    Assignee: Recurium IP Holdings, LLC
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • COMBINATIONS
    Publication number: 20230053946
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and another inhibitor (such as a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor), along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230054767
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Hooman Izadi, Peter Qinhua Huang, Sayee Gajanan Hegde, Joseph Robert Pinchman, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230054854
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 23, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Hooman Izadi, Peter Qinhua Huang, Joseph Robert Pinchman, Brant Clayton Boren, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230042653
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: February 9, 2023
    Inventors: Ahmed Abdi Samatar, Jianhui Ma, Jiali Li, Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, Fernando Donate
  • COMBINATIONS
    Publication number: 20230008362
    Abstract: Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
    Type: Application
    Filed: December 16, 2020
    Publication date: January 12, 2023
    Inventors: Ahmed Abdi Samatar, Jiali Li, Hooman Izadi, Peter Qinhua Huang, Brant Clayton Boren, Joseph Robert Pinchman, Kevin Duane Bunker, Fernando Donate
  • CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL
    Publication number: 20230002426
    Abstract: Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.
    Type: Application
    Filed: November 12, 2020
    Publication date: January 5, 2023
    Inventors: Sunny Abraham, Brant Clayton Boren, Sobhana Babu Boga, Aditya Krishnan Unni, Peter Qinhua Huang, Kevin Duane Bunker, Benjamin Anthony Pratt
  • SALTS AND FORMS OF AN ESTROGEN RECEPTOR MODULATOR
    Publication number: 20220389006
    Abstract: Salts of Compound A and forms described herein are estrogen receptor alpha modulators. Such salts and/or forms can be are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer.
    Type: Application
    Filed: November 2, 2020
    Publication date: December 8, 2022
    Inventors: Peter Qinhua Huang, Sayee Gajanan Hegde, Kevin Duane Bunker, John Knight, Deborah Helen Slee
  • PROCESS FOR MAKING [1.1.1]PROPELLANE
    Publication number: 20220324775
    Abstract: Processes of making [1.1.1]propellane utilize reaction conditions that include reacting 1,1-dibromo-2,2-bis(chloromethyl)cyclopropane with an effective amount of solid magnesium.
    Type: Application
    Filed: August 12, 2020
    Publication date: October 13, 2022
    Inventors: Aditya Krishnan Unni, Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker
  • NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR
    Publication number: 20220273666
    Abstract: Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 1, 2022
    Inventors: Joseph Robert Pinchman, Aditya Krishnan Unni, Yosef Shamay, Kevin Duane Bunker, Peter Qinhua Huang
  • BCL-2 PROTEIN INHIBITORS
    Publication number: 20220265834
    Abstract: Various Bcl-2 protein inhibitors are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments the Bcl-2 protein inhibitors are compounds or pharmaceutically acceptable salts of the following Formula (I), where the variables in Formula (I) are defined herein.
    Type: Application
    Filed: July 8, 2020
    Publication date: August 25, 2022
    Inventors: Joseph Robert Pinchman, Kevin Duane Bunker, Peter Qinhua Huang
  • ESTROGEN RECEPTOR MODULATORS
    Publication number: 20220235050
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.
    Type: Application
    Filed: April 4, 2022
    Publication date: July 28, 2022
    Inventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
  • BENZAMIDE COMPOUNDS
    Publication number: 20220226314
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Application
    Filed: March 28, 2022
    Publication date: July 21, 2022
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • Benzamide compounds
    Patent number: 11344546
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: May 31, 2022
    Assignee: Recurium IP Holding, LLC
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • Continuous flow processes for making bicyclic compounds
    Patent number: 11339103
    Abstract: Processes for making bicyclic compounds and precursors thereof, and particularly for making [1.1.1]propellane and bicyclo[1.1.1]pentane and derivatives thereof, utilize continuous flow reaction methods and conditions. A continuous process for making [1.1.1]propellane can be conducted under reaction conditions that advantageously minimize clogging of a continuous flow reactor. A continuous flow process can be used to make precursors of [1.1.1]propellane.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: May 24, 2022
    Assignee: RECURIUM IP HOLDINGS, LLC
    Inventors: Joseph Robert Pinchman, Kevin Duane Bunker, Matthew M. Bio, Christopher Breen, Andrew M. Clausen, Yuanqing Fang, Hui Li, Jillian W. Sheeran
  • Estrogen receptor modulators
    Patent number: 11339162
    Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: May 24, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
  • MACROCYCLIC COMPOUNDS
    Publication number: 20220144854
    Abstract: Disclosed are macrocyclic compounds of formula (I) comprising a 2-carboxy indole ring. Such compounds, and their pharmaceutically acceptable salts, are useful as Mcl-1 (myeloid cell leukemia-1) inhibitors. The compounds may be used in treating a disease or condition, such as cancer.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 12, 2022
    Inventors: Junhu Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sobhana Babu Boga, Sunny Abraham, Brant Clayton Boren, Wanlong Jiang, Sunil Paliwal
  • Benzamide compounds
    Patent number: 11318134
    Abstract: Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as cancer and tumors, as well as viral infections such as HIV.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: May 3, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Joseph Robert Pinchman, Peter Qinhua Huang, Kevin Duane Bunker, Rakesh Kumar Sit, Ahmed Abdi Samatar
  • ESTROGEN RECEPTOR MODULATORS FOR TREATING MUTANTS
    Publication number: 20220125769
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Application
    Filed: January 5, 2022
    Publication date: April 28, 2022
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate
  • Estrogen receptor modulators for treating mutants
    Patent number: 11278532
    Abstract: Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ER?).
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: March 22, 2022
    Assignee: Recurium IP Holdings, LLC
    Inventors: Ahmed Abdi Samatar, Jiali Li, Jianhui Ma, Sayee Gajanan Hegde, Peter Qinhua Huang, Kevin Duane Bunker, Fernando Donate